120351-90-8

Basic information

• Product Name: Ethanamine, 2-(2-fluorophenoxy)- (9CI)
• Synonyms: Ethanamine, 2-(2-fluorophenoxy)- (9CI);[2-(2-fluorophenoxy)ethyl]amine hydrochloride;2-(2-fluorophenoxy)ethanamine(SALTDATA: HCl);2-(2-Fluorophenoxy)
• CAS NO: 120351-90-8
• Molecular Formula: C₈H₁₀FNO
• Molecular Weight: 155.1695032
• Product Categories: HALIDE;Amines;Aromatics
• Mol File: 120351-90-8.mol

Chemical Properties

• Boiling Point: 241.3°Cat760mmHg
• Flash Point: 99.7°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.0362mmHg at 25°C
• Refractive Index: 1.508
• Sensitive: Air Sensitive
• CAS DataBase Reference: Ethanamine, 2-(2-fluorophenoxy)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanamine, 2-(2-fluorophenoxy)- (9CI)(120351-90-8)
• EPA Substance Registry System: Ethanamine, 2-(2-fluorophenoxy)- (9CI)(120351-90-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 120351-90-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethanamine, 2-(2-fluorophenoxy)(9CI) is used as an antiviral agent for inhibiting herpes viruses. Its unique molecular structure allows it to target and interfere with the replication and life cycle of herpes viruses, thereby providing a potential treatment option for individuals suffering from herpes infections.
The specific application reason for its use in the pharmaceutical industry is due to its ability to inhibit herpes viruses, making it a valuable asset in the development of antiviral medications and therapies. This innovative compound holds promise in addressing the challenges posed by herpes virus infections and improving patient outcomes.

InChI:InChI=1/C8H10FNO/c9-7-3-1-2-4-8(7)11-6-5-10/h1-4H,5-6,10H2

Upstream product

• 350707-57-2 2-(2-(2-fluorophenoxy)ethyl)isoindoline-1,3-dione 
• 367-12-4 2-fluorophenol 
• 193220-21-2 1-(2-bromoethoxy)-2-fluorobenzene 

Downstream Products

• 1066676-07-0 C₂₅H₂₅FN₄O₂ 
• 1037411-43-0 (S)-3-(2-cyanophenoxy)-N-(2-(2-fluorophenoxy)ethyl)-2-hydroxypropan-1-aminium trifluoroacetate 
• 110696-49-6 2-{3-[2-(2-fluorophenoxy)-ethylamino]-1-propyl}-3(2H)-pyridazinone 
• 113641-25-1 5-[2-(2-Fluoro-phenoxy)-ethylamino]-2-isopropyl-2-(3,4,5-trimethoxy-phenyl)-pentanenitrile 
• 138803-33-5 1-(6-Chloro-pyridazin-3-yloxy)-3-[2-(2-fluoro-phenoxy)-ethylamino]-propan-2-ol 

Relevant articles and documents

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents

A series of benzamide scaffolds were designed and synthesized by the thiazinone ring opening of PBTZ169, and N-benzyl 3,5-dinitrobenzamides were finally identified as anti-TB agents in this work. 3,5-Dinitrobenzamides D5, 6, 7, and 12 exhibit excellent in vitro activity against the drug susceptive Mycobacterium tuberculosis H37Rv strain (MIC: 0.0625 μg/mL) and two clinically isolated multidrug-resistant strains (MIC 0.016-0.125 μg/mL). Compound D6 displays acceptable safety and better pharmacokinetic profiles than PBTZ169, suggesting its promising potential to be a lead compound for future antitubercular drug discovery.

Synthesis of new (arylcarbonyloxy)aminopropanol derivatives and the determination of their physico-chemical properties

Eight hydrochlorides of 3-{2-[(2/4-fluorophenoxy)-ethylamino]}-2- hydroxypropyl-4-alkoxybenzoates and four hydrochlorides of 3-tert-butylamino-2- hydroxypropyl-4-butoxybenzoates were prepared as potential antagonists of the β1-adrenergic receptor (beta-blockers). A multistep synthesis of these compounds is described as well as their detailed analytical characterization. The pharmacokinetic properties of these weak base compounds are significantly influenced by their acid-base dissociation constant, pK a. The knowledge of this value is crucial for new drug development. This paper is aimed at developing a methodology that utilizes pH-dependent 1H NMR spectroscopy for its routine analysis. The selected predicted physico-chemical parameters of the new (arylcarbonyloxy)aminopropanols (i.e., aryloxyaminopropanol derivatives) were compared with the model drugs esmolol and flestolol. [Figure not available: see fulltext.]

Two-fragment α-adrenolytics 4. Synthesis of phosphorylated derivatives of 2-aryloxyethylamines and N-phenylpiperazine

The reactions of 3-chloropropylphosphonates, 3-chloropropylthiophosphonates, or 3-chloropropylphosphinates with 2-aryloxyethylamines or N-phenylpiperazine afford the corresponding 3-(2-aryloxyethylamino)propylphosphonates and -phosphinates or 3-(4-phenylpiperazin-1-yl)propylphosphonates and -phosphinates. The compounds obtained exhibit α-adrenolytic and hypotensive activities, the latter being found to depend on the substituents at the P atom.